billHR1163Event Monday, May 4, 2026Analyzed

Prove It Act

Neutral

Summary

H.R. 1163, the Prove It Act, requires federal agencies to provide greater transparency in regulatory impact analysis for small businesses. The bill is procedural and does not authorize direct spending. It has moderate bipartisan support and is moving through committee, but lacks direct market implications for publicly traded companies.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.The bill is procedural and does not authorize any spending.
  • 2.No specific public companies are materially affected.
  • 3.The legislative momentum is moderate with bipartisan cosponsorship.

Market Implications

This bill has no direct market implications. It does not affect any sector's revenue, margins, or investment thesis. The procedural changes could marginally impact the pace of future regulations but are too uncertain to trade on.

Full Analysis

The Prove It Act (H.R. 1163) was introduced in February 2025 and has advanced through committee with amendments. It was placed on the Union Calendar on May 4, 2026, indicating it is ready for House floor consideration. The bill amends the Administrative Procedure Act to require agencies to include indirect costs in regulatory flexibility analyses and allows small entities to petition the SBA Chief Counsel to review agency certifications that a rule will not significantly impact small businesses. No direct funding is authorized; the impact is regulatory and procedural. The bill's primary effect would be to increase compliance burdens on federal agencies during rulemaking, potentially slowing down new regulations that could increase costs for small businesses. However, the bill does not create or eliminate any specific government programs, contracts, or funding streams. As a result, there is no direct revenue or cost impact on publicly traded companies. No tickers are recommended because no company's revenue or competitive position is directly tied to this legislative action. Firms that assist with regulatory compliance (e.g., consulting companies) may see indirect demand, but the effect is too diffuse and speculative to assign causal chains. The legislative path forward includes a House floor vote and potential Senate action on companion bill S. 495. Given the current divided Congress, passage is uncertain but plausible.

Connected Signals

Matched on shared policy language across AI analyses, with ticker & timing weight